Skip to content

Assessment of Noninvasive Neuromodulation in a Group of Traumatic Brain Injured Patients and Healthy Volunteers

Effects of Neurobiological Therapy With Asymmetric Radio-electric Conveyer (REAC) in Diffuse Axonal Injury: a Randomized Controlled Trial.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07373366
Enrollment
60
Registered
2026-01-28
Start date
2025-04-01
Completion date
2027-05-01
Last updated
2026-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

TRAUMATIC BRAIN INJURY, DIFFUSE AXONAL INJURY, NEUROMODULATION, RADIOELECTRIC ASSIMETRIC CONVEYER

Brief summary

Background: Severe traumatic brain injury, particularly diffuse axonal injury (DAI), often leads to lasting neurological issues. Cerebral dysfunction in DAI can be evaluated by monitoring cerebral electrical activity (CEA) through EEG. The radio electric asymmetric conveyer (REAC) is a noninvasive method designed to rebalance cellular polarity via endogenous bioelectric fields and modulate CEA. This technique may alter CEA, which can be detected using quantitative EEG (qEEG). Objective: To assess qEEG changes following DAI and brain wave alterations after a REAC protocol in this group. Methods: In this prospective, randomized, double-blind clinical trial, DAI patients will be assigned to active or sham groups for 19 sessions of either true or sham REAC following ICU discharge. Interventions include one Neuro Postural Optimization session and 18 NPPO-BWO-G sessions (up to four per day). The main outcome is to evaluate changes in qEEG patterns through population brain electrical mapping after REAC therapies.

Detailed description

Traumatic brain injury (TBI) is a leading cause of death and disability globally, significantly affecting the quality of life for patients and caregivers. In the United States, traumatic brain injury is the leading cause of death for people aged 1 to 45 and a major risk factor for morbidity and mortality in politrauma cases. Although epidemiological data in Brazil are limited, studies indicate that TBI is a significant public health issue, primarily impacting the country's young and economically active population. Automobile accidents and falls are primary causes of traumatic brain injury, with incidence rates highest among young adults (20 to 29 years) and individuals over 80 years old. TBI is a highly heterogeneous condition, with multiple classification systems that emphasize distinct aspects such as the underlying mechanism of injury, clinical severity, radiological characteristics, and pathophysiological processes. These classifications play an important role in standardizing data collection, identifying prognostic factors, and informing the selection of appropriate therapeutic approaches tailored to individual cases. From a pathophysiological perspective, traumatic brain injury (TBI) causes damage through primary lesions-direct energy transfer to the brain at trauma-and secondary effects, which involve cellular and molecular changes occurring for hours to weeks post-injury. Diffuse axonal injury (DAI) is a type of lesion in TBI that leads to significant brain dysfunction and affects roughly 40% of patients, making it a leading cause of neurological problems in survivors. Clinically, it is defined as a coma lasting more than 6 hours after TBI, excluding cases caused by ischemic brain injury or intracranial masses. Detecting this condition during routine exams in TBI patients can be challenging, as DAI-related abnormalities are often missed by standard CT or MRI scans and may require advanced imaging techniques to identify structural changes in the central nervous system. From a neurological perspective, TBI can result in a wide range of cognitive, behavioral, and sensory-motor changes that may affect the patient's quality of life. Cognition encompasses the processes involved in acquiring knowledge and includes factors such as thought, language, memory, reasoning, and task execution, which are considered important for intellectual development. Although TBI is strongly linked to cognitive dysfunction, effective treatment remains difficult. While cognitive rehabilitation therapies have shown benefits in some studies, results are inconsistent. Drug therapies for post-TBI cognitive disorders have proven ineffective. The limited effectiveness of conventional cognitive rehabilitation in DAI patients has led to the exploration of new therapies. Neuromodulation techniques, both invasive and noninvasive, offer promising options by targeting specific brain regions to alter activity and support recovery. Radio-electric asymmetric conveyer (REAC) technology is a noninvasive technique that was first described by Rinaldi and Fontani. REAC neurobiological modulation with specific protocols such as neuro-postural-optimization (NPO) and neuro-psycho-physical-optimization - brain wave optimization-G (NPPO-BWO-G) is a safe, established technique with proven therapeutic benefits for various neurological and psychiatric disorders. Given the significant brain damage and multiple disabling neurological sequelae, in severe TBI patients, combined with the limited efficacy of conventional pharmacological and cognitive rehabilitation interventions, REAC may be a promising therapeutic approach for affected patients. We will conduct a randomized clinical trial to assess REAC's effects in patients with DAI. GOALS Primary Endpoint • To evaluate the qEEG changes in patients with subacute/chronic DAI, following REAC neuromodulation. Secondary Endpoint * To evaluate the qEEG changes in adults free of neurological conditions, following REAC neuromodulation. * To evaluate cognitive and humor changes in adults free of neurological conditions, following REAC neuromodulation.

Interventions

DEVICESubjects in the intervention group receive low-frequency radioelectric therapy

The intervention is based on two treatment protocols, the neuro-postural optimization in single aplication and brain-waves optimization in 18 sessions. This protocol is exclusive for the present study.

DEVICESham, the device simulates a therapy session

The device simulates a therapy session

Sponsors

University of Sao Paulo
Lead SponsorOTHER
Istituto Rinaldi Fontana
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Intervention model description

Patient selection Medical record, radiology, participation consent Step 1 (pre-intervention) qEEG, TCD and brain4care up to 3 days before the start of REAC sessions Step 2 (intervention) NPO neuromodulation (single session) Step 3 (intervention) NPPO-GW neuromodulation (18 sessions) Step 4 (post-intervention) qEEG, TCD and brain4care up to 3 days after the end of REAC sessions Follow-up discharge, 3m and 6m - mRankin, GOSE, DASS 21

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* DAI diagnostic and consent for participation with the next of kin for each eligible patient

Exclusion criteria

* Open TBI * History of chronic neurological conditions

Design outcomes

Primary

MeasureTime frame
Observe if there are significant changes in the electroencephalographic pattern, compared between the groups.Six months

Secondary

MeasureTime frameDescription
Observe if there are significant clinical improvement determined by the modified Rankin scale between the groups.six monthsThe modified Rankin scale has scores from 0 to 5, where 5 is the worst outcome (severe disability and remaining in bed), whereas 0 is the absence of any limitation (total recovery).
Observe if there are significant clinical improvement determined by the Glasgow outcome scale between the groups.Six monthsThe extended Glasgow outcome scale (GOSE) has scores from 1 to 8, considering upper limbs and/or lower limbs disability. 1 is the worst outcome (death), whereas 8 is the total recovery of upper limbs.

Countries

Brazil

Contacts

CONTACTSérgio Brasil, MD. PhD.
sbrasil@alumni.usp.br+5511981210990
CONTACTAlessandra C Renck, MD. PhD.
alerenck@alumni.usp.br+5511981211114

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026